LES ECHOS – The European Commission’s ongoing review of legislation governing the pharmaceutical, life sciences and biotechnology industries raises many questions, including the financing of innovation and the duration of protection.
The Covid-19 epidemic has highlighted both the good and the bad of the European system. The cohesion and solidarity between all the Member States has been a strength. Europe has existed on a political level in this unprecedented crisis. The pandemic made it possible to bring together strong societal values – the right to health for all – and the absolute necessity of economic competitiveness and R&D funding.
A large American pharma company, Pfizer, was surprised by its ability – in less than a year – to test and produce on the world market a breakthrough innovation developed by a small German biotech company, BioNTech.